Log in

Log in

2014

Birgegård G. A new publication is Does anything work for anaemia in myelofibrosis? Best Pract Res Clin Haematol. 2014 Jun;27(2):175-85.

2013

Birgegård G. Pharmacological management of essential thrombocythemia. Expert Opin Pharmacother. 2013 Jul;14(10):1295-306.

2011

Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O. Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. J Clin Oncol. 2011 May 2.

Abelsson J, Merup M, Birgegård G, Weis Bjerrum O, Brinch L, Brune M, Johansson P, Kauppila M, Lenhoff S, Liljeholm M, Malm C, Remes K, Vindelöv L, Andréasson B. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. 2011 May 9.

2010

Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, and Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216-20.

Tobiasson M, Alyass B, Söderlund S, Birgegård G. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Med Oncol. 2010;27:105-7.

2009

Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson j, Marcher C, Andersen MT, Bjerrum OW and Hasselbalch HC. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14: 331-34.

2008

Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Moller MB, Hasselbalch HC. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; 87: 847-50.

Landgren O, Goldin LR, Kristinsson SY, Samuelsson J, Bjorkholm M. Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden. Blood 2008; 112: 2199-2204. Read more »

Palmblad J, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Mauritzson N, Westin J, Samuelsson J & Birgegård G. Serum thrombopoietin and soluble IL-6 receptor levels after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci 2008; 5: 87-91. Read more »

Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment of patients with polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 136-37. Read more »

2007

Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G & Engström-Laurent A. No effect of anagrelide on marrow fibrosis in patients with chronic myeloproliferative disorders, estimated with hyaluronan and reticulin staining. Med Oncol 2007; 24: 63-70. Read more »

2006

Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L, Brune M, Leblanc K, Kutti J, Birgegard G & the Swedish Group for Myeloproliferative Disorders. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Br J Haematol. 2006; 135: 367-73. Read more »

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, M Merup, Linder O, Bjorkholm M, Pahl H, & Birgegard G. A phase II trial therapy in polycythemia vera and essential thrombocythemia of pegylated interferon a-2b. Feasibility, clinical and biological effects and impact on quality of life. Cancer 2006, 106: 2397-405. Read more »

Samuelsson J, Mutschler M, Birgegård G, , Gram-Hansen P, , Björkholm M & Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon a-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006; 91: 1281-82.

2005

Andreasson B, Löfvenberg E, Westin J for the Swedish MPD group. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol. 2005; 74: 489-95.

2004

Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Hematologica 2004; 89: 520-27.

2002

Merup M, Kutti J, Birgegård G, Mauritzson N, Björkholm M, Markevärn B, Malm C, Westin J, Palmblad J, Samuelsson J. Negligable clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002; 19: 79-86.

 

Member Login